Exosens Drops 2.78% Mid-Session Despite Deutsche Bank's Recommendation
Exosens fell by 2.78% to 56 euros this Tuesday, January 13th at midday, in a technical correction movement after an RSI reaching 88, while Deutsche Bank maintains its 'hold' recommendation and raises its price target to 52 euros.
Deutsche Bank Maintains 'Hold' Recommendation
This Tuesday, January 13th, Deutsche Bank maintained its 'hold' recommendation on Exosens, while raising its price target from 49 euros to 52 euros. This moderate revision reflects the analyst's caution due to a valuation considered stretched after a surge of nearly 150% over the year. The stock indeed shows a weekly performance of 6.87% and a three-month increase of 28.88%, supported by a series of major contracts in the defense sector. Technically, this Tuesday's decline is part of a natural consolidation phase after testing the resistance threshold of 57.60 euros. An RSI at 88 places the stock in an extreme overbought situation, a rarely reached level suggesting a short-term exhaustion of the buying momentum. However, the price remains well above its moving averages, with a 50-day MA at 46.92 euros and a 200-day MA at 41.91 euros, confirming a decidedly bullish underlying trend. The MACD histogram remains positive at 0.97, indicating the persistence of favorable momentum despite this technical pullback.
Tuesday's Decline Follows Major Contract Announcement
Tuesday's decline comes a day after a session marked by the announcement of a major order. On January 12th, Exosens announced it had secured its largest contract to date for its fifth-generation light intensifying tubes, with an order of over 7,000 units from ACTinBlack Group, to be delivered between 2027 and 2028. According to the company, this 5G technology offers a 30% improvement in overall performance and up to a 35% increase in detection ranges compared to standard tubes. The defense optronics specialist maintains an ambitious 2025 guidance, expecting revenue growth at the high end of the 15 to 20% range and an increase in adjusted EBITDA at the lower end of the 20 to 25% range compared to 2024. The group benefits from a favorable context linked to the increase in European military budgets and the strengthening of night vision capabilities of the armed forces. The monthly volatility of the stock stands at 11.86%, a moderate level given the amplitude of recent fluctuations, while a beta of 0.04 confirms a low correlation with Parisian indices.
